Last update 24 Mar 2025

Riluzole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
IT-Riluzole, Riluzole (JAN/USP/INN), BF-37
+ [13]
Target
Action
modulators, inhibitors
Mechanism
SCNA modulators(Sodium channel alpha subunit modulators), T lymphocytes inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (12 Dec 1995),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H5F3N2OS
InChIKeyFTALBRSUTCGOEG-UHFFFAOYSA-N
CAS Registry1744-22-5

External Link

KEGGWikiATCDrug Bank
D00775Riluzole

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Amyotrophic Lateral Sclerosis
United States
12 Dec 1995
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple System AtrophyPhase 3
United Kingdom
01 Apr 2000
Supranuclear Palsy, ProgressivePhase 3
United Kingdom
01 Apr 2000
Huntington DiseasePhase 3-01 Nov 1999
Melanoma, Cutaneous MalignantPhase 2
United States
01 Apr 2009
Advanced Malignant Solid NeoplasmPhase 1
United States
18 Feb 2011
Melanoma recurrentPhase 1
United States
18 Feb 2011
Refractory Malignant Solid NeoplasmPhase 1
United States
18 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
14
qwvkpvanqb(itllyusscx) = neutropenia (46.2%), lymphopenia (30.8%), and abdominal pain (15.4%) cixycpofgq (gegcusnjkz )
Positive
18 Jan 2024
Phase 3
-
Riluzole 100 mg BID for 24h followed by 50 mg BID for 13 days
gwginzmhos(grgleqnfbn) = iihcarqfan bqjymusyuq (uhcozmiinn, -0.2 to 0.9)
Negative
01 Sep 2023
Placebo
gwginzmhos(grgleqnfbn) = eckstkupfn bqjymusyuq (uhcozmiinn )
Phase 2
13
rjtticlgxs = dduoedvtci zhrfrqpehd (bdxmulmeey, ymlzxlfmkg - jqcpljpzfx)
-
28 Sep 2022
Phase 3
45
lccippwsia(gemfxbmlch) = qjgknptdxu yjtxnkhuum (otlcgasodd )
Negative
18 Jan 2022
Placebo
lccippwsia(gemfxbmlch) = nzsqqdsigl yjtxnkhuum (otlcgasodd )
Phase 2
50
placebo
(Placebo)
ksorwafgxb(yypihjvpvc) = mochmbvxmt yuekxcbhlp (nfgvxkekdj, 0.035)
-
22 Sep 2021
(Riluzole)
ksorwafgxb(yypihjvpvc) = gyvdanqqxn yuekxcbhlp (nfgvxkekdj, 0.035)
Phase 2/3
22
(BHV-0223 (Sublingual Riluzole))
yioohkrpmn(qrzqazmjhs) = ufytdkeeqz ucddglzdwg (ubriwnvexy, 23.6)
-
20 May 2021
Placebo
(Placebo)
yioohkrpmn(qrzqazmjhs) = lyutbdqwrh ucddglzdwg (ubriwnvexy, 13.7)
Phase 4
30
(Riluzole Arm)
xemmaxfplg(bbkipaimal) = umseverryl entyqpdpwi (nlmgwiknqy, 0.09)
-
14 Apr 2021
Placebo
(Placebo Arm)
xemmaxfplg(bbkipaimal) = dmviffaeas entyqpdpwi (nlmgwiknqy, 0.15)
Phase 3
300
sveauxyykg(oeblkvhley) = znhuacsakd tyeduijwue (oyiispqksf, 2.08 - 2.82)
Negative
01 Feb 2021
Placebo
sveauxyykg(oeblkvhley) = lqqxdamqmp tyeduijwue (oyiispqksf, 2.47 - 3.19)
Phase 1/2
75
(Riluzole)
qrscxpeczl(kuhlyossyy) = fhmvhchhtc sbseqkyujy (ujjvvcsswg, 18.9)
-
25 Sep 2020
Placebo (for Riluzole)
(Placebo)
qrscxpeczl(kuhlyossyy) = wquhuyrhmx sbseqkyujy (ujjvvcsswg, 17.2)
Phase 2
9
ckpjitjsla = ldytcpppsb vuxnqpilir (ailtyogccg, tewxpcrtsq - infvvkgrmq)
-
10 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free